NS Pharma SRL
1.2 FTEThe score of NS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +69 % Total assets -14 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
NS Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 35,970 € | ||||
| Equity | 269,360 € | ||||
| Cash | 12,799 € | ||||
| EBITDA | 153,766 € | ||||
| Total assets | 691,656 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 02 Feb 2026
- Year ended 30 Jun 2024filed on 27 Feb 2025
- Year ended 30 Jun 2023filed on 19 Feb 2024
- Year ended 30 Jun 2022filed on 01 Feb 2023
- Year ended 30 Jun 2021filed on 04 Feb 2022
NS Pharma's financial analysis
- Solvency38.9%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of NS Pharma
NS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0822.653.238
- VAT number
- BE0822653238
- Peppol
- Registered · 0208:0822653238 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 27 Jan 2010
- Registered office
- 5060 Sambreville
- Size
- Micro · 1.2 FTE
- Latest accounts
- 2025 · filed on 02 Feb 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
NS Pharma (SRL) has been based in Sambreville since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 35,970 € and equity of 269,360 €; its revenue is not published. With 1.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 38.9%, below the median of its sector (41.5%).
Companies similar to NS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Vanachter Retail sale of pharmaceutical products Puurs-Sint-Amands · balance sheet 692,130 €
- Apoteek Ginderbuiten Retail sale of pharmaceutical products Mol · balance sheet 692,197 €
- Dierick & Verleyen Mouscron Retail sale of pharmaceutical products Mouscron · balance sheet 692,455 €
- Pharmacie Piedboeuf Retail sale of pharmaceutical products Chaudfontaine · balance sheet 690,407 €
- Domicapharma Retail sale of pharmaceutical products Sint-Laureins · balance sheet 690,248 €
- De Wase Apotheek Retail sale of pharmaceutical products Sint-Niklaas · balance sheet 689,221 €
- Phaladel Retail sale of pharmaceutical products Braine-le-Comte · balance sheet 694,145 €
- Pharmacare Retail sale of pharmaceutical products Herent · balance sheet 695,856 €
Frequently asked questions about NS Pharma
What is the revenue of NS Pharma?
NS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of NS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0822653238 for NS Pharma, if the company is VAT-registered. Its company number (CBE) is 0822.653.238.
Where is the registered office of NS Pharma?
According to the CBE register, the registered office of NS Pharma is in 5060 Sambreville.
What is the equity of NS Pharma?
At the close of the 2025 financial year, the equity of NS Pharma amounts to 269,360 €, a solvency of 38.9% of total assets.
How many people work at NS Pharma?
1.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages NS Pharma?
The register lists 1 active mandates at NS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of NS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →